Skip to main content
CELADON PHARMACEUTICALS PLC logo

CELADON PHARMACEUTICALS PLC — Investor Relations & Filings

Ticker · CEL ISIN · GB00BDQYGP38 LEI · 213800YXCATORT475807 IL Manufacturing
Open in API
Filings indexed 128 across all filing types
Latest filing 2023-03-17 Regulatory Filings
Country GB United Kingdom
Listing IL CEL

About CELADON PHARMACEUTICALS PLC

https://celadonpharma.co.uk/

Celadon Pharmaceuticals PLC is a vertically integrated pharmaceutical company focused on the research, cultivation, manufacturing, and supply of cannabinoid-based medicines. The company operates a licensed, 100,000 sq ft facility with EU-GMP certification for the indoor, hydroponic cultivation of high-THC cannabis and the extraction of cannabinoid Active Pharmaceutical Ingredients (API). Its primary focus is the chronic pain market, and it is conducting an MHRA conditionally approved clinical trial to generate data supporting the use of its medicines for this condition. Additionally, Celadon has an in-house research and development program focused on intellectual property generation and is involved in developing a licensed cannabinoid treatment for Autism Spectrum Disorder through a biopharma partnership.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1925 characters) and its primary content is an announcement regarding a 'Price Monitoring Extension' for a security on the London Stock Exchange, referencing the 'RNS Number' and stating that the information is provided by RNS, the news service of the London Stock Exchange, approved by the FCA. This is a general regulatory announcement that does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA). Since it is a standard, brief regulatory notification distributed via the RNS system, the most appropriate classification is the general regulatory filing category.
2023-03-17 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1942 characters) and contains the header 'RNS Number : 4118T'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates a general regulatory announcement that does not fit into the specific categories like ER, 10-K, or DIV. Therefore, the most appropriate classification is the general regulatory filing category, RNS.
2023-03-17 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1925 characters) and contains the header 'RNS Number : 4115T'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a brief announcement disseminated via the RNS system regarding a market operational event—fits best under the general Regulatory Filings category, as there is no specific code for trading mechanism updates, and it is not a report itself (ruling 2 applies, but RNS is a better fit than RPA since it's a direct regulatory update rather than an announcement *of* a report).
2023-03-17 English
Successful Update to Home Office Licence
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' header and contains information typical of a regulatory news service announcement from the London Stock Exchange. The content details a specific operational update: the successful update of a Home Office Licence allowing for the commercial sale of GMP pharmaceutical cannabis, following MHRA registration. This is a material, non-financial operational announcement. It is not a full annual report (10-K), an earnings release (ER), or a detailed management discussion (MDA). Since it is a formal announcement disseminated via RNS regarding a significant operational milestone, and it doesn't fit into the more specific categories like Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate classification is the general regulatory announcement category, RNS.
2023-03-14 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1942 characters) and contains the header 'RNS Number : 9534S'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates a general regulatory announcement that does not fit into the specific categories like ER, 10-K, or DIV. Therefore, it should be classified as a Regulatory Filing (RNS), which serves as the general regulatory announcement fallback category.
2023-03-14 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1925 characters) and contains the header 'RNS Number : 9525S'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a brief, specific operational announcement distributed via the RNS system—fits best under the general Regulatory Filings category, as it is not a core financial report (like 10-K, IR, ER) or a specific corporate action like a dividend or management change. It is a miscellaneous regulatory notification.
2023-03-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.